Manufacture of fusion protein successfulPacificGMP and Vasgene Therapeutics, both headquartered in California, recently announced the successful completion of a recombinant fusion protein, which will now be used in a phase 1 clinical trial.

PacificGMP is a contract manufacturer and industry leader in using technology to advance and develop biologics. The single-use technology the company specializes in is noteworthy for reducing cross-contamination risks. On its website, the company lists several benefits of using single-use/disposable products in the healthcare setting, saying it will "minimize facility requirements and decrease need for utilities, infrastructure, operations and labor." 

Vasgene Therapeutics is headquartered in Los Angeles and is a clinical stage company with special expertise in vascular biology. The company focuses on the development of cancer treatments.

"We selected PacificGMP as our contract manufacturing organization because of their considerable expertise in scale-up and cGMP manufacturing of proteins using single use technology as well as for their commitment to being a partner in our efforts to bring this product to the clinic," said Parkash Gill, co-founder and director of Vasgene. "We are very pleased with PacificGMP's manufacture of Vasgene's recombinant fusion protein to support development of this cancer therapeutic agent."
Share To:

Strategic Sourceror

Post A Comment:

0 comments so far,add yours